Saliba J.; Deleuze-Masquefa C.; Iskandarani A.; El Eit R.; Hmadi R.; Mahon F.-X.; Bazarbachi A.; Bonnet P.-A.; Nasr R.
(Lippincott Williams and Wilkins; PHILADELPHIA530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA, 2014)
Imatinib, the first-generation tyrosine kinase inhibitor, revolutionized the therapeutic management of chronic myeloid leukemia (CML) and is highly effective in inducing remissions and prolonging the survival of CML patients. ...